The aging/cancer connection

American Journal of the Medical Sciences

Volumn 315, Issue 1, 1998, Pages 40-49

  Nusbaum, Neil J ^a,b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROTEIN BCL 2; PROTEIN P53; TELOMERASE;

AGING; APOPTOSIS; BREAST CANCER; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE DEFICIENCY; LUNG SMALL CELL CANCER; REVIEW; SOMATIC MUTATION; SURVIVAL RATE; TELOMERE; UNITED STATES;

EID: 0031984388     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199801000-00008     Document Type: Review

References (104)

1. McBean AM, Warren JL, Babish JD. Measuring the incidence of cancer in elderly Americans using Medicare claims data. Cancer. 1994; 73:2417-25.
2. Poldenak AP. Projected numbers of cancers diagnosed in the US elderly population, 1990 through 2030. Am J Public Health. 1994;84:1313-16.
3. Miller AB. How do we interpret the "bad news" about cancer? JAMA. 1994; 271:468.
4. Antman K. Presidential address. J Clin Oncol. 1995; 13:2980-89.
5. Manton KG, Wrigley JM, Cohen HJ, Woodbury MA. Cancer mortality, aging, and patterns of comorbidity in the United States: 1968 to 1986. J Gerontol. 1991;46:S225-34.
6. Nusbaum N. What good is it to get old? Med Hypotheses. 1996;47:77-9.
7. Ramel C. Evolutionary aspects of human cancer. Pharmacogenetics. 1992;2:344-9.
8. Rattan SIS. Gerontogenes: Real or virtual? FASEB J. 1995;2:284-6.
9. Franceschi C, Monti D, Cossarizza A, Fagnoni F, Passeri G, Sansoni P. Aging, longevity, and cancer. Ann N Y Acad Sci. 1991;621:428-40.
10. Cooper EL. Invertebrates can tell us something about senescence. Aging Clin Exp Res. 1994;6:5-23.
11. Chandra M, Riley MGI, Johnson DE. Spontaneous neoplasms in aged Sprague-Dawley rats. Arch Toxicol. 1992; 66:496-502.
12. Martin GM. Genetic and environmental modulations of chromosomal stability: Their roles in aging and oncogenesis. Ann N Y Acad Sci. 1991;621:401-17.
13. Stanbridge EJ. Summation and synthesis: From the cancer cell biology point of view. In: Yang SS, Warner HH, eds. The Underlying Molecular, Cellular and Immunological Factors in Cancer and Aging. New York: Plenum Press; 1993:307-14.
14. Rao KM, Cohen HJ. Actin cytoskeletal network in aging and cancer. Mutât Res. 1991;256:139-48.
15. Cotton DW, Rogers S. Ageing, cancer, and mitochondrial deterioration. Lancet. 1993;341:281-2.
16. Nusbaum N. Genetic bases for sideroblastic anemia. Am J Hematol. 1991;37:41-4.
17. Wallace DC, Shoffner JM, Trounce I, Brown MD, Ballinger SW, Corral-Debrinski M, et al. Mitochondrial DNA mutations in human degenerative diseases and aging. Biochim Biophys Acta. 1995;1271:141-51.
18. Wallace DC. Mitochondrial DNA variation in human evolution, degenerative disease, and aging. Am J Hum Genet. 1994;57:201-23.
19. Cortopassi G, Wang E. Modelling the effects of age-related mtDNA mutation accumulation. Biochim Biophys Acta. 1995; 1271:171-6.
20. Kirn NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011-5.
21. Slagboom PE, Droog S, Boomsa DI. Genetic determination of telomere size in humans. Am J Hum Genet. 1994;55:876-82.
22. Martin GM. Genetic modulation of telomeric terminal restriction-fragment length. Am J Hum Genet. 1994;55:866-9.
23. Allsopp RC, Chang E, Kashefi-Aazam M, et al. Telomere shortening is associated with cell division in vitro and in vivo. Exp Cell Res. 1995;220:194-200.
24. Zhang L, Kokkonen G, Roth GS. Identification of neuronal programmed cell death in situ in the striatum of normal adult rat brain and its relationship to neuronal death during aging. Brain Res. 1995; 677:177-9.
25. Ishizaki Y, Burne JF, Raff MC. Autocrine signals enable chondrocytes to survive in culture. J Cell Biol. 1994;126:1069-77.
26. Mountz JD, Zhou T, Wu J, Wang W, Su X, Cheng J. Regulation of apoptosis in immune cells. J Clin Immunol. 1995; 15:1-16.
27. Lu Q-L, Abel P, Foster CS, Lalani E-N. bcl-2: Role in epithelial differentiation and oncogenesis. Hum Pathol. 1996;27:102-10.
28. Kinzler KW, Vogelstein B. Life (and death) in a malignant tumour. Nature. 1996;379:19-20.
29. Hickman JA, Apoptosis induced by cancer drugs. Cancer Metastasis Rev. 1992; 11:121-39.
30. Farlie PG, Dringen R, Rees SM, Kannourakis, Bernard O. bcl-2 transgene expression can protect neurons against developmental and induced cell death. Proc Nat Acad Sci USA. 1995;92:4397-401.
31. Karsan A, Yeé E, Kaushansky K, Harlan JM. Cloning of a human bcl-2 homologue. Blood. 1996; 87:3089-96.
32. Desoize B. Anticancer drug resistance and inhibition of apoptosis. Anticancer Res. 1994; 14:2291-4:
33. Feng J, Funk WD, Wang S-S, et al. The RNA component of human telomerase. Science. 1995;269:1236-41.
34. Haber DA. Telomeres, cancer, and immortality. N Engl J Med. 1995;332:955-6.
35. Bruel A, Benoît G, DeNay D, Brown S, Lanotte M. Distinct apoptotic responses in maturation sensitive and résistant t(15;17) acute promyelocytic leukemia NB4 cells: 9-cis retinoic acid induces apoptosis independent of maturation and bcl-2 expression. Leukemia. 1995;9:1173-84.
36. Rogaia D, Grignani FR, Grignani F, Nicoletti I, Pelicci PG. The acute promyelocytic leukemia-specific PML/RARI fusion protein reduces the frequency of commitment to apoptosis upon factor deprivation of GM-CSF-dependent myeloid cells. Leukemia. 1995;9:1467-72.
37. Nakamura T, Pichel JG, Williams-Simons L, Westphal H. An apoptotic defect in lens differentiation caused by human p53 is rescued by a mutant allele. Proc Natl Acad Sci USA. 1995;92:6142-6.
38. Chiarugi V, Magnelli L, Ruggiero M. Apoptosis, senescence, immortalization and cancer. Pharmacol Res. 1994;30:301-15.
39. Ludwig H, Fritz E, Neuda J, Durie BGM. Patient preferences for interferon alfa in multiple myeloma. J Clin Oncol. 1997;15:1672-9.
40. Leikin S. The role of adolescents in decisions concerning their cancer therapy. Cancer. 1993;71:3342-6.
41. Trebbi CK. Treatment compliance in childhood and adolescence. Cancer. 1993;71:3441-9.
42. Meyer RM, Browman GP, Samosh ML, et al. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol. 1995; 13:2386-93.
43. Sonneveld P, de Ridder M, van der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol. 1995; 13:2530-9.
44. Newshaffer CJ, Penberthy L, Desch CE, Retchin SM, Whittemore M. The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer. Arch Intern Med. 1996; 156:85-90.
45. Wyckoff J, Greenberg H, Sanderson R, Wallach P, Balducci L. Breast irradiation in the older woman. J Am Geriatr Soc. 1994;42:150-2.
46. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. N Engl J Med. 1995;333:1444-55.
47. Roetzheim RG, Fox SA, Leake B. Physician-reported determinants of screening mammography in older women: The impact of physician and practice characteristics. J Am Geriatr Soc. 1995;43:1398-402.
48. Monfardini S, Yancik R. Cancer in the elderly: Meeting the challenge of an aging population. J Natl Cancer Inst. 1993;85:532-8.
49. Chung M, Chang HR, Bland Kl, Wanebo HJ. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer. 1996;77:97-103.
50. CroweJP,'Gordon NH, Shenk RR, Zollinger RM, Brumberg D J, Suck J. Age does not predict breast cancer outcome. Arch Surg. 1994; 129:483-8.
51. Busch E, Kemeny M, Fremgen A, Osteen RT, Wincheter DP, Clive RE. Patterns of breast cancer care in the elderly. Cancer. 1996;78:101-11.
52. Newschaffer CJ, Penberthy L, Desch CE, Retchin SM, Whittemore M. The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer. Arch Intern Med. 1996, 156:840-90.
53. Goel V, Olivotto I, Hislop TUG, Sawka C, Coldman A, Holowaty EJ. Patterns of initial management of nodenegative breast cancer in two Canadian provinces. Can Med AssocJ. 1997; 156:25-35.
54. Guadagnoli E, Shapiro C, Gurwitz JH, Silliman RA, Weeks JC, Borbas C, et al. Age-related patterns of care: Evidence against ageism in the treatment of early-stage breast cancer. J Clin Oncol. 1997; 15:2338-44.
55. Caplan LS, Helzisouer KJ, Shapiro S, Freedman LS, Coates RJ, Edwards BK. System delay in breast cancer in whites and blacks. Am J Epidemiol. 1995; 142:804-12.
56. Chew FS, O'Reilly MAR, Schuckenbrock CM, RelyeaChew A, Foley HT, O'Reilly PMR. Medicolegal aspects of breast cancer in U.S. federal medical facilities. Mil Med. 1996; 161:329-33.
57. Stockton D, Davies T, Day N, McCann J. Retrospective study of reasons for improved survival in patients with breast cancer in East Anglia: Earlier diagnosis or better treatment? BMJ. 1997;314:472-5.
58. Tabar L, Fagerberg G, Chen H-H, Duffy SW, Smart CR, Gad A, et al. Efficacy of breast cancer screening by age. Cancer. 1995;75:2507-17.
59. de Koning HJ, Boer R, Warmerdam PG, Beemsterboer PMM, van der Maas PJ. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. J Natl Cancer Inst. 1995;87:1217-23.
60. Taylor DII, McPherson K, Parbhoo S, Perry N. Response of women aged 65-74 to invitation for screening for breast cancer by mammography: A pilot study in London, UK. J Epidemiol Community Health. 1996;50:77-80.
61. Kattlove H, Liberati A, Keeler E, Brook RH. Benefits and costs of screening and treatment for early breast cancer. JAMA. 1995;273:142-8.
62. Satriano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994; 120:104-10.
63. Chen H-H, Tabar L, Fagerberg G, Duffy SW. Effect of breast cancer screening after age 65. J Med Screening. 1995;2:10-4.
64. Grodstein F, Stampfer MJ, Colditz GA, Wille« WC, Manson JA, Joffe M, et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997; 336:1769-75.
65. Brinton LA, Schairer C. Postmenopausal hormone-replacement therapy: Time for a reappraisal? N Engl J Med. 1997;336:1821-2.
66. Christman K, Muss HB, Case LD, Stanley V. Chemotherapy of metastatic breast cancer in the elderly: The Piedmont Oncology Association experience. JAMA. 1992; 268:57-62.
67. Harris JE. The treatment of cancer in an aging population. JAMA. 1992; 268:96-7.
68. Aisner J. Extensive-disease small cell lung cancer. J Clin Oncol. 1996; 14:658-65.
69. Shepherd FA, Amdemichael E, Evans WK, Chalvardjian P, Hogg-Johnson S, Coates R, et al. Treatment of small cell lung cancer in the elderly. J Am Geriatr Soc. 1994;42:64-70.
70. Brown JS, Eraut D, Trask C, Davison AG. Age and the treatment of lung cancer. Thorax. 1996;51:564-8.
71. Nusbaum NJ. How do geriatric patients recover from surgery? South Med J. 1996;950-7.
72. Fong Y, Blumgart LH, Fortner JG, Brennan MF. Pancreatic or liver resection for malignancy is safe and effective for the elderly. Ann Surg. 1995; 222:426-37.
73. Arbman G, Nilsson E, Störgen-Fordell V, Sjödahl R. A short diagnostic delay is more important for rectal cancer than for colonie cancer. Eur J Surg. 1996; 162:899-904.
74. Martin IG, Young S, Sue-Ling H, Johnston D. Delays in the diagnosis of esophagogastric cancer: VA consecutive case series. BMJ. 1997;314:467-71. ;
75. Kemppainen M, Raiha I, Rajala T, Sourander L. Delay in diagnosis of colorectal cancer in elderly patients. Age Ageing. 1993; 22:260-264.
76. Grant R, Liang BC, Page MA, Crane DL, Greenberg HS, Junck L. Age influences chemotherapy response to astrocytomas. Neurology. 1995;45:929-33.
77. DeLima M, Ghaddar H, Pierce S, Estes E. Treatment of newly-diagnosed acute myelogenous leukemia in patients aged 80 years and above. Br J Haematol. 1996;91:89-95.
78. Manoharan A, Baker RI, Kyle PW. Low-dose combination chemotherapy for acute myeloid leukemia in elderly patients: A novel approach. Am J Hematol. 1997;55:115-7.
79. Nusbaum N, Gonzalez J. Failure to detect asymptomatic colorectal cancer. Cancer Research, Therapy and Control. 1995;4:237r40.
80. Mânsson A, Anderson H, Colleen S. Time lag to diagnosis of bladder cancer: Influence of psychosocial parameters and level of health-care provision. Scand J Urol Nephrol. 1993;27:363-9.
81. Pendleton N, Jefferson MF, Dixon GR, Myskow MW, Horan MA. Correlates of tumor size, gender, cell type, and metastasis of resected non-small cell lung cancer and age. J Gerontol A Biol Sci Med Sci, 1996;51:B50-3.
82. Vose JM, Armitage JO, Weisenburger DD, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1988;6:1838-44.
83. Tishelman C. Who cares? Patients' descriptions of age-related aspects of cancer and care in Stockholm. Cancer Nurs. 1993; 16:270-82.
84. Shell JA, Smith CK. Sexuality and the older person with cancer. Oncol Nurs Forum. 1994;21:553-8.
85. Mazur DJ, Merz JF. Older patients' willingness to trade off urologie adverse outcomes for a better chance at fiveyear survival in the clinical setting of prostate cancer. J Am Geriatr Soc. 1995;43:979-84.
86. Ershler WB. The influence of an aging immune system on cancer incidence and progression. J Gerontol A Biol Sci Med Sci. 1993;48:B3-7.
87. Arranz E, O'Mahony S, Barton JR, Ferguson A. Immunosenescence and mucosal immunity. Gut. 1992;33:882-6.
88. al-Rayes H, Pachas W, Mirza N, Ahern DJ, Geha RS, Vercelli D. IgE regulation and lymphokine patterns in aging humans. J Allergy Clin Immunol. 1992;90:630-6.
89. Sansoni P, Cossarizza A, Brianti V, Fagnoni F, Snelli G, Monti D, et al. Lymphocyte subsets and natural killer cell activity in healthy old people and centenarians. Blood. 1993;82:2767-73.
90. Rothstein G. Hematopoiesis in the aged. Blood 1993;82:2601-4.
91. Kutza J, Kayc D, Murasko DM. Basal natural killer cell activity of young versus elderly humans. J Gerontol A Biol Sci Med Sci. 1995;50:B110-6.
92. Wiedermann CJ, Niedermühlbichler M, Beimpold II, Braunsteiner H. In vitro activation of neutrophils of the aged by recombinant human growth hormone. J Infect Dis. 1991; 164:1017-20.
93. McLachlan JA, Serkin CD, Morrey KM, Bakouche O. Antitumoral properties of aged human monocytes. J Immmunol. 1995; 154:832-43.
94. Daynes RA, Araneo BA, Ershler WB, Maloney C, Li G-Z, Ryu S-Y. Altered regulation of IL-6 production with normal aging. J Immunol. 1993; 150:5219-30.
95. Ershler WB. Tumors and aging. In: Yang SS, Warner HH, eds. The Underlying Molecular, Cellular and Irnmunological Factors in Cancer and Aging. New York: 'Plenum Press; 1993:77-92.
96. Cerhan JR, Wallace RB, Folsom AR, Potter JD, Munger RG, Prineas RJ. Transfusion history and cancer risk in older women. Ann Intern Med. 1993; 119:8-15.
97. Miller RA. Aging and cancer: Another perspective. J Geron"tol A Biol Sci Med Sci. 1993;48:B8-9.
98. Mackall CL, Fleisher TA, Brown:MR, Andrich MP, Chen CG, Feuerstein IM, et al. Age, thymopoiesis, and CD4+ lymphocyte regeneration after, intensive chemotherapy. N Engl J Med. 1995;332:143-9.'
99. Franceschi C, Monti D, Cossarizza A, Fagnoni F, Passeri G, Sansoni P. Aging, longevity, and cancer. Ann N Y Acad Sci. 1991;621:428-40.
100. Peris TT, Wood ER. Acute care costs of the oldest old. Arch Intern Med. 1996; 156:754-60.
101. Manton KG, Vaupel JW. Survival after the age of 80 in V the United States, Sweden, France, England, and Japan. N Engl J Med. 1995;333:1232-5.
102. McLaughlin TJ, Soumerai SB, Wilison DJ, Gurwitz JH, Borbas C, Guadagnoli E, et al. Adherence to national guidelines for drug treatment of suspected myocardial infarction. Arch Intern Med. 1996; 156:799-805.
103. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, et al. Granulocyte-macrophage colonystimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med. 1995;332:1671-7.
104. Dombert H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med. 1995;332:1678-83.